Label: PYRAZINAMIDE tablet

  • NDC Code(s): 33342-447-03, 33342-447-07, 33342-447-09, 33342-447-10, view more
    33342-447-11, 33342-447-12, 33342-447-15
  • Packager: Macleods Pharmaceuticals Limited
  • Category: HUMAN PRESCRIPTION DRUG LABEL
  • DEA Schedule: None
  • Marketing Status: Abbreviated New Drug Application

Drug Label Information

Updated September 16, 2020

If you are a consumer or patient please visit this version.

  • DESCRIPTION

    Pyrazinamide, USP  the pyrazine analogue of nicotinamide, is an antituberculous agent. It is a white crystalline powder, stable at room temperature, and sparingly soluble in water. Pyrazinamide USP has the following structural formula:


    pyrazinamide-structure

    Each pyrazinamide tablet, USP for oral administration contains 500 mg of pyrazinamide and the following inactive ingredients: corn starch, colloidal silicon dioxide, magnesium stearate, povidone, sodium starch glycolate and talc

  • CLINICAL PHARMACOLOGY

    Pyrazinamide is well absorbed from the GI tract and attains peak plasma concentrations within 2 hours.
    Plasma concentrations generally range from 30 to 50 mcg/mL with doses of 20 to 25 mg/kg. It is widely distributed in body tissues and fluids including the liver, lungs and cerebrospinal fluid (CSF). The CSF concentration is approximately equal to concurrent steady-state plasma concentrations in patients with inflamed meninges.1 Pyrazinamide is approximately 10% bound to plasma proteins.2

    The half-life (t1/2) of pyrazinamide is 9 to 10 hours in patients with normal renal and hepatic function. The plasma half-life may be prolonged in patients with impaired renal or hepatic function. Pyrazinamide is hydrolyzed in the liver to its major active metabolite, pyrazinoic acid. Pyrazinoic acid is hydroxylated to the main excretory product, 5-hydroxypyrazinoic acid.3

    Approximately 70% of an oral dose is excreted in urine, mainly by glomerular filtration within 24 hours.3

    Pyrazinamide may be bacteriostatic or bactericidal against Mycobacterium tuberculosis depending on the concentration of the drug attained at the site of infection. The mechanism of action is unknown. In vitro and in vivo the drug is active only at a slightly acidic pH.

    Susceptibility Testing
    For specific information regarding susceptibility test interpretive criteria and associated test methods and quality control standards recognized by FDA for this drug, please see: https://www.fda.gov/STIC.

  • INDICATIONS & USAGE

    Pyrazinamide is indicated for the initial treatment of active tuberculosis in adults and children when combined with other antituberculous agents. (The current recommendation of the CDC for drug- susceptible disease is to use a six-month regimen for initial treatment of active tuberculosis, consisting of isoniazid, rifampin and pyrazinamide given for 2 months, followed by isoniazid and rifampin for 4 months.* 4 )

    (Patients with drug-resistant disease should be treated with regimens individualized to their situation. Pyrazinamide frequently will be an important component of such therapy.)

    (In patients with concomitant HIV infection, the physician should be aware of current recommendations of CDC. It is possible these patients may require a longer course of treatment.)

    It is also indicated after treatment failure with other primary drugs in any form of active tuberculosis.

    Pyrazinamide should only be used in conjunction with other effective antituberculous agents.

    *See recommendations of Center for Disease Control (CDC) and American Thoracic Society for complete regimen and dosage recommendations.4

  • CONTRAINDICATIONS

    Pyrazinamide is contraindicated in persons:
    • with severe hepatic damage.
    • who have shown hypersensitivity to it.
    • with acute gout.


  • WARNINGS

    Patients started on pyrazinamide should have baseline serum uric acid and liver function determinations.
    Those patients with preexisting liver disease or those at increased risk for drug related hepatitis (e.g.,alcohol abusers) should be followed closely.

    Pyrazinamide should be discontinued and not be resumed if signs of hepatocellular damage or hyperuricemia accompanied by an acute gouty arthritis appear.

  • PRECAUTIONS

    General

    Pyrazinamide inhibits renal excretion of urates, frequently resulting in hyperuricemia which is usually asymptomatic. If hyperuricemia is accompanied by acute gouty arthritis, pyrazinamide should be discontinued.

    Pyrazinamide should be used with caution in patients with a history of diabetes mellitus, as management may be more difficult.

    Primary resistance of M. tuberculosis to pyrazinamide is uncommon. In cases with known or suspected drug resistance, in vitro susceptibility tests with recent cultures of M. tuberculosis against pyrazinamide and the usual primary drugs should be performed. There are few reliable in vitro tests for pyrazinamide resistance. A reference laboratory capable of performing these studies must be employed.

    Information for Patients

    Patients should be instructed to notify their physicians promptly if they experience any of the following: fever, loss of appetite, malaise, nausea and vomiting, darkened urine, yellowish discoloration of the skin and eyes, pain or swelling of the joints.

    Compliance with the full course of therapy must be emphasized, and the importance of not missing any doses must be stressed.

    Laboratory Tests

    Baseline liver function studies [especially ALT (SGPT), AST (SGOT) determinations] and uric acid levels should be determined prior to therapy. Appropriate laboratory testing should be performed at periodic intervals and if any clinical signs or symptoms occur during therapy.

    Drug/Laboratory Test Interactions

    Pyrazinamide has been reported to interfere with ACETEST® and KETOSTIX® urine tests to produce a pink-brown color. 5

    Carcinogenesis , Mutagenesis , Impairment of Fertility 6,7,8

    In lifetime bioassays in rats and mice, pyrazinamide was administered in the diet at concentrations of up to 10,000 ppm. This resulted in estimated daily doses for the mouse of 2 g/kg, or 40 times the maximum human dose, and for the rat of 0.5 g/kg, or 10 times the maximum human dose. Pyrazinamide was not carcinogenic in rats or male mice and no conclusion was possible for female mice due to insufficient numbers of surviving control mice.


    Pyrazinamide was not mutagenic in the Ames bacterial test, but induced chromosomal aberrations in human lymphocyte cell cultures.

    Pregnancy: Teratogenic Effects

    Animal reproduction studies have not been conducted with pyrazinamide. It is also not known whether pyrazinamide can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Pyrazinamide should be given to a pregnant woman only if clearly needed.

    Nursing Mothers

    Pyrazinamide has been found in small amounts in breast milk. Therefore, it is advised that pyrazinamide be used with caution in nursing mothers taking into account the risk-benefit of this therapy.9

    Pediatric Use

    Pyrazinamide regimens employed in adults are probably equally effective in pediatric patients. 4,10,11 Pyrazinamide appears to be well tolerated in pediatric patients


    Geriatric Use 12

    Clinical studies of pyrazinamide did not include sufficient numbers of patients aged 65 and over to determine whether they respond differently from younger patients. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic or renal function, and of concomitant disease or other drug therapy.

    It does not appear that patients with impaired renal function require a reduction in dose. It may be prudent to select doses at the low end of the dosing range, however.13

  • ADVERSE REACTIONS

    General
    Fever, porphyria and dysuria have rarely been reported. Gout (see PRECAUTIONS).

    Gastrointestinal
    The principal adverse effect is a hepatic reaction (see WARNINGS). Hepatotoxicity appears to be dose related, and may appear at any time during therapy. GI disturbances including nausea, vomiting and anorexia have also been reported.

    Hematologic and Lymphatic
    Thrombocytopenia and sideroblastic anemia with erythroid hyperplasia, vacuolation of erythrocytes and increased serum iron concentration have occurred rarely with this drug. Adverse effects on blood clotting mechanisms have also been rarely reported.

    Other
    Mild arthralgia and myalgia have been reported frequently. Hypersensitivity reactions including rashes, urticaria, and pruritus have been reported. Fever, acne, photosensitivity, porphyria, dysuria and interstitial nephritis have been reported rarely.

  • OVERDOSAGE

    Overdosage experience is limited. In one case report of overdose, abnormal liver function tests developed. These spontaneously reverted to normal when the drug was stopped. Clinical monitoring and supportive therapy should be employed. Pyrazinamide is dialyzable.13

  • DOSAGE & ADMINISTRATION

    Pyrazinamide should always be administered with other effective antituberculous drugs. It is administered for the initial 2 months of a 6-month or longer treatment regimen for drug-susceptible patients. Patients who are known or suspected to have drug-resistant disease should be treated with regimens individualized to their situation. Pyrazinamide frequently will be an important component of such therapy.
    Patients with concomitant HIV infection may require longer courses of therapy. Physicians treating such patients should be alert to any revised recommendations from CDC for this group of patients.
    Usual dose: Pyrazinamide is administered orally, 15 to 30 mg/kg once daily. Older regimens employed 3 or 4 divided doses daily, but most current recommendations are for once a day. Three grams per day should not be exceeded. The CDC recommendations do not exceed 2 g per day when given as a daily regimen (see table).
    Alternatively, a twice weekly dosing regimen (50 to 70 mg/kg twice weekly based on lean body weight) has been developed to promote patient compliance with a regimen on an outpatient basis. In studies evaluating the twice weekly regimen, doses of pyrazinamide in excess of 3 g twice weekly have been administered. This exceeds the recommended maximum 3 g/daily dose. However, an increased incidence of adverse reactions has not been reported.
    The table is taken from the CDC-American Thoracic Society joint recommendations:4
    Recommended Drugs for the Initial Treatment of Tuberculosis in Children and Adults

     
    Daily Dose*
     
    Maximal Daily Dose in Children and Adults
    Twice Weekly Dose
    Drug
    Children
    Adults
      
    Children
    Adults
    Isoniazid
    10 to 20 mg/kg
    PO or IM
    5 mg/kg
    PO or IM
    300 mg
    20 to 40 mg/kg
    Max. 900 mg
    15 mg/kg
    Max. 900 mg
    Rifampin
    10 to 20 mg/kg
    PO
    10 mg/kg
    PO
    600 mg
    10 to 20 mg/kg
    Max. 600 mg
    10 mg/kg
    Max. 600 mg
    Pyrazinamide
    15 to 30 mg/kg
    PO
    15 to 30 mg/kg
    PO
    2 g
    50 to 70 mg/kg
    50 to 70 mg/kg
    Streptomycin
    20 to 40 mg/kg
    IM
    15 mg/kg**
    IM
    1 g**
    25 to 30 mg/kg
    IM
    25 to 30 mg/kg
    IM
    Ethambutol
    15 to 25 mg/kg
    PO
    15 to 25 mg/kg
    PO
    2.5 g
    50 mg/kg
    50 mg/kg

      Definition of abbreviations: PO = perorally; IM = intramuscularly.
    *Doses based on weight should be adjusted as weight changes.
    **In persons older than 60 yrs of age the daily dose of streptomycin should be limited to 10 mg/kg with a maximal dose of 750 mg.

  • HOW SUPPLIED

    Pyrazinamide Tablets, USP 500 mg are round, white to off white uncoated, scored tablets with notches, debossed "F" above the score and "43" below the score and plain on other side.

    Tablets are supplied in the following strengths and package configurations:



    Package configuration
    NDC number
    Bottles of 10
    33342-447-03
    Bottles of 30
    33342-447-07
    Bottles of 60
    33342-447-09
    Bottles of 90
    33342-447-10
    Bottles of 100
    33342-447-11
    Bottles of 500
    33342-447-15
    Carton of 100 Tablets
    (10 x 10 unit dose)
    33342-447-12

    Store at 20° to 25° C (68° F to 77° F); excursions permitted between 15° to 30° C (59° F to 86° F) [see USP Controlled Room Temperature].

    Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure.


  • REFERENCES

    1.Drug Information, American Hospital Formulary Service. American Society of Hospital Pharmacists. Bethesda, MD 1991.
    2.USPDI, Drug Information for the Health Care Professional. United States Pharmacopeial Convention, Inc. Rockville, MD 1991:1B:2226-2227.
    3.Goodman-Gilman A, Rall TW, Nies AS, Taylor P. The Pharmacological Basis of Therapeutics, ed 8. New York, Pergamon Press. 1990;1154.
    4.Treatment of tuberculosis and tuberculosis infection in adults and children. Am Rev Respir Dis.1986;134:363-368.
    5.Reynolds JEF, Parfitt K, Parsons AV, Sweetman-SC. Martindale The Extra Pharmacopoeia, ed 29. London, The Pharmaceutical Press. 1989;569-570.
    6.Bioassay of pyrazinamide for possible carcinogenicity. National Cancer Institute Carcinogenesis Technical Report Series No. 48, 1978.
    7.Zerger E, Anderson B, Haworth S, Lawlor T, Mortelmans K, Speck W. Salmonella mutagenicity tests: III. Results from the testing of 255 chemicals. Environ Mutagen. 1987;9 (Suppl 9):1109.
    8.Roman IC, Georgian L. Cytogenetic effects of some antituberculosis drugs in vitro. Mutation Research. 1977;48:215-224.
    9.Holdiness M. Antituberculosis drugs and breast-feeding. Arch Intern Med. 1984;144:1888.
    10.Turcios N, Evans H. Preventing and managing tuberculosis in children. J Resp Dis. 1989;10(6)(Jun):23.
    11.Starke JR. Multidrug therapy for tuberculosis in children. Pediatr Infec Dis J. 1990;9:785-793.
    12.Specific requirements on content and format of labeling for human prescription drugs; proposed addi-tion of "geriatric use" subsection in the labeling. Federal Register. 1990;55(212)(Nov1):46134-46137.
    13.Stamathakis G, Montes C, Trouvin JH, et al. Pyrazinamide and pyrazinoic acid pharmacokinetics in
    patients with chronic renal failure. Clinical Nephrology. 1988;30:230-234.


    Manufactured for:
    Macleods Pharma USA, Inc.
    Plainsboro, NJ 08536

    Manufactured by:
    Macleods Pharmaceutical Ltd.
    Daman, (U.T.), INDIA

    Revised: September 2020

  • PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

    Pyrazinamide Tablets USP 500mg
    Pack count:100s
    NDC : 33342-447-11


    100s

    Pyrazinamide Tablets USP 500mg
    Pack count:500s
    NDC : 33342-447-15


    500s


  • INGREDIENTS AND APPEARANCE
    PYRAZINAMIDE 
    pyrazinamide tablet
    Product Information
    Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC:33342-447
    Route of AdministrationORAL
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    PYRAZINAMIDE (UNII: 2KNI5N06TI) (PYRAZINAMIDE - UNII:2KNI5N06TI) PYRAZINAMIDE500 mg
    Inactive Ingredients
    Ingredient NameStrength
    STARCH, CORN (UNII: O8232NY3SJ)  
    POVIDONE (UNII: FZ989GH94E)  
    SODIUM STARCH GLYCOLATE TYPE A POTATO (UNII: 5856J3G2A2)  
    TALC (UNII: 7SEV7J4R1U)  
    SILICON DIOXIDE (UNII: ETJ7Z6XBU4)  
    MAGNESIUM STEARATE (UNII: 70097M6I30)  
    Product Characteristics
    ColorWHITE (White to off white) Score2 pieces
    ShapeROUND (Round uncoated scored tablets with notches) Size12mm
    FlavorImprint Code F;43
    Contains    
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC:33342-447-0310 in 1 BOTTLE; Type 0: Not a Combination Product07/27/2020
    2NDC:33342-447-0730 in 1 BOTTLE; Type 0: Not a Combination Product07/27/2020
    3NDC:33342-447-0960 in 1 BOTTLE; Type 0: Not a Combination Product07/27/2020
    4NDC:33342-447-1090 in 1 BOTTLE; Type 0: Not a Combination Product07/27/2020
    5NDC:33342-447-11100 in 1 BOTTLE; Type 0: Not a Combination Product07/27/2020
    6NDC:33342-447-15500 in 1 BOTTLE; Type 0: Not a Combination Product07/27/2020
    7NDC:33342-447-1210 in 1 BLISTER PACK; Type 0: Not a Combination Product07/27/2020
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    ANDAANDA21254107/27/2020
    Labeler - Macleods Pharmaceuticals Limited (862128535)
    Establishment
    NameAddressID/FEIBusiness Operations
    Macleods Pharmaceuticals Limited918608365ANALYSIS(33342-447) , LABEL(33342-447) , MANUFACTURE(33342-447) , PACK(33342-447)